



BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")

Result of Annual General Meeting

Alderley Park, 4th May 2023 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies with improved tolerability and anti-cancer activity, announces that at the Company's Annual General Meeting held today at 11:30 am at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 31st March 2023.

Details of proxy votes received prior to the meeting will be made available on the Company's website at <https://bivictrix.com/investor-relations/>. The proxy results were as follows:

RESOLUTION NUMBER	VOTES FOR	VOTES AGAINST	VOTES WITHHELD	VOTES TOTAL
1	19,276,083	0	0	19,276,083
2	19,276,083	0	0	19,276,083
3	13,276,083	6,000,000	0	19,276,083
4	19,276,083	0	0	19,276,083
5	19,276,083	0	0	19,276,083
6	19,276,083	0	0	19,276,083
7	19,276,083	0	0	19,276,083

For more information, please contact:

BiVictriX Therapeutics plc

Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Chairman

Email: info@bivictrix.com

SP Angel Corporate Finance LLP (NOMAD and Broker)

David Hignell, Kasia Brzozowska (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)

Tel: +44 (0) 20 3470 0470

Panmure Gordon (UK) Limited (Joint Broker)

Rupert Dearden/Freddy Crossley/Emma Earl

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Mary-Jane Elliott, Namrata Taak,
Genevieve Wilson, Emmalee Hoppe

Tel: +44 (0) 20 3709 5700

Email: Bivictrix@consilium-comms.com



About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or “Bi-Cygni® fingerprints”, on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company’s novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com